D-Galactose pentaacetate
Based on 1 Customer Validation
D-Galactose pentaacetate inhibits leucine-induced insulin release. D-Galactose pentaacetate can be used for the research of persistent hyperinsulinemia in childhood or insulinoma.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 97.0%
- CAS. Nr.: 25878-60-8
- Formel: C16H22O11
- Molecular Weight:390.34
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-P0276
GIP, humanInsulin Secretion Stimulator -
HY-P2093
S961Insulin Receptor Antagonist -
HY-P2542
GIP (3-42), humanGIP Receptor Agonist -
HY-124097
HNMPA-(AM)3Insulin Receptor Inhibitor -
HY-19694
BRD7552PDX1 Inducer -
HY-P3579
Gastric Inhibitory Peptide, porcineInsulinotropic Polypeptide -
HY-W010271
(2S,3R,4S)-4-HydroxyisoleucineAnti-diabetic Agent -
HY-115461
MID-1MG53-IRS-1 Interaction Disruptor -
HY-W145497
D-(+)-SorboseSweetener -
HY-15481
KU14RKATP Channel Inhibitor -
HY-112720
AGL-2263Insulin Receptor Inhibitor -
HY-W039923
β-D-Galactose pentaacetateInsulin Antagonist
Biologische Aktivität
Beschreibung
Chemical Information
-
CAS. Nr. 25878-60-8
-
Appearance Powder
-
Molecular Weight 390.34
-
Formel C16H22O11
-
Color White to off-white
-
SMILES
CC(O[C@H]1[C@H]([C@H](OC([C@@H]1OC(C)=O)OC(C)=O)COC(C)=O)OC(C)=O)=O
-
Synonyms
Pentaacetyl-D-galactopyranose
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 100 mg/mL (256.19 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.40 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.40 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (277 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. W J Malaisse, et al. Inhibition of insulin release by alpha- and beta-D-galactose pentaacetate. Int J Mol Med. 1998 Sep;2(3):331-2. [Content Brief]
[2]. M M Kadiata, et al. Opposite effects of D-glucose pentaacetate and D-galactose pentaacetate anomers on insulin release evoked by succinic acid dimethyl ester in rat pancreatic islets. Life Sci. 1999;64(9):751-4. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5619 mL | 12.8093 mL | 25.6187 mL | 64.0467 mL |
| 5 mM | 0.5124 mL | 2.5619 mL | 5.1237 mL | 12.8093 mL | |
| 10 mM | 0.2562 mL | 1.2809 mL | 2.5619 mL | 6.4047 mL | |
| 15 mM | 0.1708 mL | 0.8540 mL | 1.7079 mL | 4.2698 mL | |
| 20 mM | 0.1281 mL | 0.6405 mL | 1.2809 mL | 3.2023 mL | |
| 25 mM | 0.1025 mL | 0.5124 mL | 1.0247 mL | 2.5619 mL | |
| 30 mM | 0.0854 mL | 0.4270 mL | 0.8540 mL | 2.1349 mL | |
| 40 mM | 0.0640 mL | 0.3202 mL | 0.6405 mL | 1.6012 mL | |
| 50 mM | 0.0512 mL | 0.2562 mL | 0.5124 mL | 1.2809 mL | |
| 60 mM | 0.0427 mL | 0.2135 mL | 0.4270 mL | 1.0674 mL | |
| 80 mM | 0.0320 mL | 0.1601 mL | 0.3202 mL | 0.8006 mL | |
| 100 mM | 0.0256 mL | 0.1281 mL | 0.2562 mL | 0.6405 mL |
D-Galactose pentaacetate Related Classifications
HY-W102387 Related Classifications
Powered by Bioz